{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:36:28Z","timestamp":1790742988224,"version":"4.1.0"},"reference-count":90,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brain, Behavior, and Immunity"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.bbi.2018.01.004","type":"journal-article","created":{"date-parts":[[2018,1,12]],"date-time":"2018-01-12T03:28:32Z","timestamp":1515727712000},"page":"456-469","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"C","title":["Treatment with the noradrenaline re-uptake inhibitor atomoxetine alone and in combination with the \u03b12-adrenoceptor antagonist idazoxan attenuates loss of dopamine and associated motor deficits in the LPS inflammatory rat model of Parkinson\u2019s disease"],"prefix":"10.1016","volume":"69","author":[{"given":"Justin D.","family":"Yssel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2472-7795","authenticated-orcid":false,"given":"Eoin","family":"O'Neill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne M.","family":"Nolan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Connor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9734-216X","authenticated-orcid":false,"given":"Andrew","family":"Harkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbi.2018.01.004_b0005","doi-asserted-by":"crossref","first-page":"11347","DOI":"10.1073\/pnas.89.23.11347","article-title":"Brain-derived neurotrophic factor augments rotational behavior and nigrostriatal dopamine turnover in vivo","volume":"89","author":"Altar","year":"1992","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.bbi.2018.01.004_b0010","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.mce.2006.03.013","article-title":"Gene expression patterns for GDNF and its receptors in the human putamen affected by Parkinson's disease: a real-time PCR study","volume":"252","author":"B\u00e4ckman","year":"2006","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.bbi.2018.01.004_b0015","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/BF00274983","article-title":"The human locus coeruleus complex: an immunohistochemical and three dimensional reconstruction study","volume":"77","author":"Baker","year":"1989","journal-title":"Exp. Brain Res."},{"key":"10.1016\/j.bbi.2018.01.004_b0020","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1046\/j.1471-4159.1997.69041438.x","article-title":"Elevation of cyclic AMP levels in astrocytes antagonizes cytokine-induced adhesion molecule expression","volume":"69","author":"Ballestas","year":"1997","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bbi.2018.01.004_b0025","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1002\/mds.21552","article-title":"Neuroinflammation in the pathophysiology of Parkinson's disease: evidence from animal models to human in vivo studies with [11C]-PK11195 PET","volume":"22","author":"Bartels","year":"2007","journal-title":"Mov. Disord."},{"key":"10.1016\/j.bbi.2018.01.004_b0030","doi-asserted-by":"crossref","first-page":"8818","DOI":"10.1073\/pnas.94.16.8818","article-title":"Intrastriatal injection of an adenoviral vector expressing glial-cell-line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson disease","volume":"94","author":"Bilang-Bleuel","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.bbi.2018.01.004_b0035","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/0006-8993(94)90534-7","article-title":"Locus coeruleus lesions potentiate neurotoxic effects of MPTP in dopaminergic neurons of the substantia nigra","volume":"668","author":"Bing","year":"1994","journal-title":"Brain Res."},{"key":"10.1016\/j.bbi.2018.01.004_b0040","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0006-8993(00)02915-2","article-title":"Towards a neuroprotective gene therapy for Parkinson\u2019s disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model","volume":"886","author":"Bj\u00f6rklund","year":"2000","journal-title":"Brain Res."},{"key":"10.1016\/j.bbi.2018.01.004_b0045","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0304-3940(94)90684-X","article-title":"Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease","volume":"172","author":"Boka","year":"1994","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.bbi.2018.01.004_b0050","doi-asserted-by":"crossref","first-page":"342","DOI":"10.2174\/1570159X12666140828220938","article-title":"Noradrenergic regulation of glial activation: molecular mechanisms and therapeutic implications","volume":"12","author":"Braun","year":"2014","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.bbi.2018.01.004_b0055","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/j.1471-4159.2009.06482.x","article-title":"The \u03b12 adrenoceptor antagonist idazoxan alleviates l-DOPA-induced dyskinesia by reduction of striatal dopamine levels: an in vivo microdialysis study in 6-hydroxydopamine-lesioned rats","volume":"112","author":"Buck","year":"2010","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bbi.2018.01.004_b0060","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/cne.902870308","article-title":"Alterations in catecholamine neurons of the locus coeruleus in senile dementia of the Alzheimer type and in Parkinson's disease with and without dementia and depression","volume":"287","author":"Chan-Palay","year":"1989","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.bbi.2018.01.004_b0065","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1126\/science.275.5301.838","article-title":"Dopaminergic neurons protected from degeneration by GDNF gene therapy","volume":"275","author":"Choi-Lundberg","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.bbi.2018.01.004_b0070","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1006\/exnr.1998.6887","article-title":"Behavioral and cellular protection of rat dopaminergic neurons by an adenoviral vector encoding glial cell line-derived neurotrophic factor","volume":"154","author":"Choi-Lundberg","year":"1998","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.bbi.2018.01.004_b0075","article-title":"Fluoxetine versus other types of pharmacotherapy for depression","author":"Cipriani","year":"2005","journal-title":"Cochrane Library"},{"key":"10.1016\/j.bbi.2018.01.004_b0080","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1016\/j.neuropharm.2012.01.028","article-title":"Contributions of central and systemic inflammation to the pathophysiology of Parkinson's disease","volume":"62","author":"Collins","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bbi.2018.01.004_b0085","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1038\/sj.gt.3301033","article-title":"Differential effects of glial cell line-derived neurotrophic factor (GDNF) in the striatum and substantia nigra of the aged Parkinsonian rat","volume":"6","author":"Connor","year":"1999","journal-title":"Gene Ther."},{"key":"10.1016\/j.bbi.2018.01.004_b0090","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1093\/jnen\/61.5.413","article-title":"Where does parkinson disease pathology begin in the brain?","volume":"61","author":"Del Tredici","year":"2002","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.bbi.2018.01.004_b0095","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1111\/j.1460-9568.2003.03014.x","article-title":"Microglial activation with atypical proinflammatory cytokine expression in a rat model of Parkinson's disease","volume":"18","author":"Depino","year":"2003","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.bbi.2018.01.004_b0100","doi-asserted-by":"crossref","first-page":"a009258","DOI":"10.1101\/cshperspect.a009258","article-title":"Parkinson\u2019s disease and parkinsonism: neuropathology","volume":"2","author":"Dickson","year":"2012","journal-title":"Cold Spring Harbor Perspect. Med."},{"key":"10.1016\/j.bbi.2018.01.004_b9000","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/j.pnpbp.2008.09.008","article-title":"Reduced efficacy of fluoxetine following MDMA (\u201cEcstasy\u201d)-induced serotonin loss in rats","volume":"32","author":"Durkin","year":"2008","journal-title":"Prog. Neuropsychopharmacol Biol. Psychiatry"},{"key":"10.1016\/j.bbi.2018.01.004_b0105","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1046\/j.1471-4159.1998.70041484.x","article-title":"Suppression of astroglial nitric oxide synthase expression by norepinephrine results from decreased NOS-2 promoter activity","volume":"70","author":"Feinstein","year":"1998","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bbi.2018.01.004_b0110","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S0197-0186(02)00049-9","article-title":"Noradrenergic regulation of inflammatory gene expression in brain","volume":"41","author":"Feinstein","year":"2002","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.bbi.2018.01.004_b0115","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1046\/j.1471-4159.1995.65020704.x","article-title":"Clonidine suppresses 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced reductions of striatal dopamine and tyrosine hydroxylase activity in mice","volume":"65","author":"Fornai","year":"1995","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bbi.2018.01.004_b0120","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/mds.1148","article-title":"Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct: evidence from the effects of the alpha2 adrenoceptor antagonist idazoxan","volume":"16","author":"Fox","year":"2001","journal-title":"Mov. Disord."},{"key":"10.1016\/j.bbi.2018.01.004_b0125","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0193-953X(05)70277-X","article-title":"Pharmacotherapy for chronic depression","volume":"19","author":"Friedman","year":"1996","journal-title":"Psychiatr. Clin. North Am."},{"key":"10.1016\/j.bbi.2018.01.004_b0130","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0165-5728(88)90017-3","article-title":"Norepinephrine inhibits gamma-interferon-induced MHC class II (Ia) antigen expression on cultured brain astrocytes","volume":"17","author":"Frohman","year":"1988","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.bbi.2018.01.004_b0135","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/0014-5793(89)81391-2","article-title":"Catecholamines increase nerve growth factor mRNA content in both mouse astroglial cells and fibroblast cells","volume":"247","author":"Furukawa","year":"1989","journal-title":"FEBS Lett."},{"key":"10.1016\/j.bbi.2018.01.004_b0140","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.it.2008.05.002","article-title":"Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression","volume":"29","author":"Gao","year":"2008","journal-title":"Trends Immunol."},{"key":"10.1016\/j.bbi.2018.01.004_b0145","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S0149-7634(00)00028-2","article-title":"The role of the locus coeruleus in the development of Parkinson's disease","volume":"24","author":"Gesi","year":"2000","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.bbi.2018.01.004_b0150","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1136\/jnnp.16.4.213","article-title":"The brain-stem lesions in Parkinsonism","volume":"16","author":"Greenfield","year":"1953","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.bbi.2018.01.004_b0155","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s002109900167","article-title":"Noradrenoceptor antagonism with idazoxan improves l-dopa-induced dyskinesias in MPTP monkeys","volume":"361","author":"Grondin","year":"2000","journal-title":"Naunyn-Schmiedeberg's Arch. Pharmacol."},{"key":"10.1016\/j.bbi.2018.01.004_b0160","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1038\/jcbfm.1990.145","article-title":"Protection against ischemia-induced neuronal damage by the \u03b12-adrenoceptor antagonist idazoxan: influence of time of administration and possible mechanisms of action","volume":"10","author":"Gustafson","year":"1990","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.bbi.2018.01.004_b0165","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1523\/JNEUROSCI.22-07-02434.2002","article-title":"Noradrenergic depletion potentiates \u03b2-amyloid-induced cortical inflammation: implications for Alzheimer's disease","volume":"22","author":"Heneka","year":"2002","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bbi.2018.01.004_b0175","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/S1474-4422(09)70062-6","article-title":"Neuroinflammation in Parkinson's disease: a target for neuroprotection?","volume":"8","author":"Hirsch","year":"2009","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.bbi.2018.01.004_b0180","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.bbi.2012.10.001","article-title":"Further characterisation of the LPS model of Parkinson\u2019s disease: a comparison of intra-nigral and intra-striatal lipopolysaccharide administration on motor function, microgliosis and nigrostriatal neurodegeneration in the rat","volume":"27","author":"Hoban","year":"2013","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.bbi.2018.01.004_b0185","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.pnpbp.2004.05.026","article-title":"Role of presynaptic \u03b1 2-adrenoceptors in antidepressant action: recent findings from microdialysis studies","volume":"28","author":"Invernizzi","year":"2004","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.bbi.2018.01.004_b0190","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.brainres.2006.06.008","article-title":"Monoaminergic neuronal activity up-regulates BDNF synthesis in cultured neonatal rat astrocytes","volume":"1108","author":"Juri\u010d","year":"2006","journal-title":"Brain Res."},{"issue":"4","key":"10.1016\/j.bbi.2018.01.004_b0195","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1046\/j.1471-4159.2003.01909.x","article-title":"Noradrenaline induces expression of peroxisome proliferator activated receptor gamma (PPAR\u03b3) in murine primary astrocytes and neurons","volume":"86","author":"Klotz","year":"2003","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bbi.2018.01.004_b0200","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1006\/bbrc.1997.7183","article-title":"Adenovirus-mediated transduction with human glial cell line-derived neurotrophic factor gene prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopamine depletion in striatum of mouse brain","volume":"238","author":"Kojima","year":"1997","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbi.2018.01.004_b0205","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1212\/WNL.0b013e31825f0451","article-title":"Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study)","volume":"79","author":"LeWitt","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.bbi.2018.01.004_b0210","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1126\/science.8493557","article-title":"GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons","volume":"260","author":"Lin","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.bbi.2018.01.004_b0215","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/nature05957","article-title":"Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo","volume":"448","author":"Lindholm","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.bbi.2018.01.004_b0220","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/nature05957","article-title":"Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo","volume":"448","author":"Lindholm","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.bbi.2018.01.004_b0225","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.pneurobio.2009.08.001","article-title":"The influence of microglia on the pathogenesis of Parkinson's disease","volume":"89","author":"Long-Smith","year":"2009","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.bbi.2018.01.004_b0230","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1046\/j.0953-816x.2001.01843.x","article-title":"Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease","volume":"15","author":"Lundblad","year":"2002","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.bbi.2018.01.004_b0235","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/jnr.20481","article-title":"Norepinephrine protects cortical neurons against microglial-induced cell death","volume":"81","author":"Madrigal","year":"2005","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.bbi.2018.01.004_b0240","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1111\/j.1471-4159.2007.04888.x","article-title":"Neuroprotective actions of noradrenaline: effects on glutathione synthesis and activation of peroxisome proliferator activated receptor delta","volume":"103","author":"Madrigal","year":"2007","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bbi.2018.01.004_b0245","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/0014-2999(93)90489-5","article-title":"Noradrenaline depletion exacerbates MPTP-induced striatal dopamine loss in mice","volume":"236","author":"Marien","year":"1993","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bbi.2018.01.004_b0250","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.brainresrev.2004.02.002","article-title":"Noradrenergic mechanisms in neurodegenerative diseases: a theory","volume":"45","author":"Marien","year":"2004","journal-title":"Brain Res. Rev."},{"key":"10.1016\/j.bbi.2018.01.004_b0255","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1006\/exnr.1998.6942","article-title":"Neuroprotective effects of the \u03b12-adrenoceptor antagonists, (+)-efaroxan and (\u00b1)-idazoxan, against quinolinic acid-induced lesions of the rat striatum","volume":"154","author":"Martel","year":"1998","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.bbi.2018.01.004_b0260","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/0306-4522(91)90345-O","article-title":"Effects of locus coeruleus lesions on parkinsonian signs, striatal dopamine and substantia nigra cell loss after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in monkeys: a possible role for the locus coeruleus in the progression of Parkinson's disease","volume":"41","author":"Mavridis","year":"1991","journal-title":"Neuroscience"},{"key":"10.1016\/j.bbi.2018.01.004_b0265","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ejphar.2009.09.054","article-title":"Noradrenaline induces IL-1ra and IL-1 type II receptor expression in primary glial cells and protects against IL-1\u03b2-induced neurotoxicity","volume":"626","author":"McNamee","year":"2010","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bbi.2018.01.004_b0270","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.neuropharm.2010.03.014","article-title":"Noradrenaline acting at \u03b2-adrenoceptors induces expression of IL-1\u03b2 and its negative regulators IL-1ra and IL-1RII, and drives an overall anti-inflammatory phenotype in rat cortex","volume":"59","author":"McNamee","year":"2010","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bbi.2018.01.004_b0275","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ijdevneu.2009.10.003","article-title":"Regulatory role of monoamine neurotransmitters in astrocytic NT-3 synthesis","volume":"28","author":"Mele","year":"2010","journal-title":"Int. J. Dev. Neurosci."},{"issue":"1\u20132","key":"10.1016\/j.bbi.2018.01.004_b0280","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0166-4328(97)00195-2","article-title":"The effects of unilateral pyramidal tract section on hindlimb motor performance in the rat","volume":"96","author":"Metz","year":"1998","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.bbi.2018.01.004_b0285","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0304-3940(94)90508-8","article-title":"Interleukin-1\u03b2, interleukin-6, epidermal growth factor and transforming growth factor-\u03b1 are elevated in the brain from parkinsonian patients","volume":"180","author":"Mogi","year":"1994","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.bbi.2018.01.004_b0290","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/0165-0270(91)90048-5","article-title":"The \u201cstaircase test\u201d: a measure of independent forelimb reaching and grasping abilities in rats","volume":"36","author":"Montoya","year":"1991","journal-title":"J. Neurosci. Methods"},{"issue":"3","key":"10.1016\/j.bbi.2018.01.004_b0295","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s002210050739","article-title":"Ground reaction forces in locomoting hemi-parkinsonian rats: a definitive test for impairments and compensations","volume":"126","author":"Muir","year":"1999","journal-title":"Exp. Brain Res."},{"key":"10.1016\/j.bbi.2018.01.004_b0300","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0006-3223(99)00173-0","article-title":"A review of the efficacy of serotonergic and noradrenergic reuptake inhibitors for treatment of major depression","volume":"46","author":"Nelson","year":"1999","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.bbi.2018.01.004_b0305","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1017\/S146114570800967X","article-title":"Noradrenaline reuptake inhibitors limit neuroinflammation in rat cortex following a systemic inflammatory challenge: implications for depression and neurodegeneration","volume":"12","author":"O'Sullivan","year":"2009","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.bbi.2018.01.004_b0310","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.1523\/JNEUROSCI.15-05-03863.1995","article-title":"Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test","volume":"15","author":"Olsson","year":"1995","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bbi.2018.01.004_b0315","series-title":"Maps and Guide to Microdissection of the Rat Brain","author":"Palkovits","year":"1988"},{"key":"10.1016\/j.bbi.2018.01.004_b0320","series-title":"A Stereotaxic Atlas of the Rat Brain","author":"Paxinos","year":"1998"},{"key":"10.1016\/j.bbi.2018.01.004_b0325","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.nurt.2008.02.003","article-title":"Treatment of Parkinson\u2019s disease with trophic factors","volume":"5","author":"Peterson","year":"2008","journal-title":"Neurotherapeutics"},{"issue":"3","key":"10.1016\/j.bbi.2018.01.004_b0330","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.brainresbull.2005.04.013","article-title":"Limits on recovery in the corticospinal tract of the rat: partial lesions impair skilled reaching and the topographic representation of the forelimb in motor cortex","volume":"66","author":"Piecharka","year":"2005","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.bbi.2018.01.004_b0335","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.chc.2005.08.002","article-title":"Pharmacotherapy of attention-deficit hyperactivity disorder in children and adolescents: update on new stimulant preparations, atomoxetine, and novel treatments","volume":"15","author":"Prince","year":"2006","journal-title":"Child Adolesc. Psychiatr. Clin. North Am."},{"key":"10.1016\/j.bbi.2018.01.004_b0340","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1002\/mds.1143","article-title":"Idazoxan, an alpha-2 antagonist, and l-DOPA-induced dyskinesias in patients with Parkinson's disease","volume":"16","author":"Rascol","year":"2001","journal-title":"Mov. Disord."},{"key":"10.1016\/j.bbi.2018.01.004_b0345","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1742-2094-1-9","article-title":"Inhibition of microglial inflammatory responses by norepinephrine: effects on nitric oxide and interleukin-1beta production","volume":"1","author":"Russo","year":"2004","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/j.bbi.2018.01.004_b0350","doi-asserted-by":"crossref","first-page":"8935","DOI":"10.1073\/pnas.92.19.8935","article-title":"Glial cell line-derived neurotrophic factor but not transforming growth factor beta 3 prevents delayed degeneration of nigral dopaminergic neurons following striatal 6-hydroxydopamine lesion","volume":"92","author":"Sauer","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.bbi.2018.01.004_b0355","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0028-3908(00)00005-8","article-title":"CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury","volume":"39","author":"Schallert","year":"2000","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bbi.2018.01.004_b0360","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1097\/00001756-199505300-00009","article-title":"BDNF attenuates the effects of intrastriatal injection of 6-hydroxydopamine","volume":"6","author":"Shults","year":"1995","journal-title":"Neuroreport"},{"key":"10.1016\/j.bbi.2018.01.004_b0365","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0165-0173(00)00030-8","article-title":"Neurotrophic factors in Alzheimer\u2019s and Parkinson\u2019s disease brain","volume":"33","author":"Siegel","year":"2000","journal-title":"Brain Res. Rev."},{"key":"10.1016\/j.bbi.2018.01.004_b0370","first-page":"699","article-title":"Neuroprotective effect of BDNF in young and aged 6-OHDA treated rat model of Parkinson disease","volume":"44","author":"Singh","year":"2006","journal-title":"Indian J. Exp. Biol."},{"key":"10.1016\/j.bbi.2018.01.004_b0375","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1471-4159.1992.tb08880.x","article-title":"Brain-derived neurotrophic factor protects dopamine neurons against 6-hydroxydopamine and N-methyl-4-phenylpyridinium ion toxicity: involvement of the glutathione system","volume":"59","author":"Spina","year":"1992","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bbi.2018.01.004_b0380","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.bbr.2003.08.016","article-title":"Behavioral and neurochemical effects of noradrenergic depletions with N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine in 6-hydroxydopamine-induced rat model of Parkinson\u2019s disease","volume":"151","author":"Srinivasan","year":"2004","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.bbi.2018.01.004_b0385","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.cytogfr.2011.05.001","article-title":"Neurotrophic factors for the treatment of Parkinson's disease","volume":"22","author":"Sullivan","year":"2011","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.bbi.2018.01.004_b0390","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.neuropharm.2005.11.022","article-title":"Effect of the attention deficit\/hyperactivity disorder drug atomoxetine on extracellular concentrations of norepinephrine and dopamine in several brain regions of the rat","volume":"50","author":"Swanson","year":"2006","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bbi.2018.01.004_b0395","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.neuroscience.2009.12.027","article-title":"A comprehensive analysis of the effect of DSP4 on the locus coeruleus noradrenergic system in the rat","volume":"166","author":"Szot","year":"2010","journal-title":"Neuroscience"},{"key":"10.1016\/j.bbi.2018.01.004_b0400","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.nbd.2009.11.004","article-title":"Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention","volume":"37","author":"Tansey","year":"2010","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.bbi.2018.01.004_b0405","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1046\/j.1471-4159.2001.00556.x","article-title":"Noradrenaline provides long-term protection to dopaminergic neurons by reducing oxidative stress","volume":"79","author":"Troadec","year":"2001","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bbi.2018.01.004_b0410","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1111\/j.1476-5381.1993.tb13623.x","article-title":"In vivo microdialysis of noradrenaline overflow: effects of \u03b1-adrenoceptor agonists and antagonists measured by cumulative concentration-response curves","volume":"109","author":"Veldhuizen","year":"1993","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bbi.2018.01.004_b0415","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.expneurol.2005.03.004","article-title":"Activation of noradrenergic transmission by \u03b12-adrenoceptor antagonists counteracts deafferentation-induced neuronal death and cell proliferation in the adult mouse olfactory bulb","volume":"194","author":"Veyrac","year":"2005","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.bbi.2018.01.004_b0420","doi-asserted-by":"crossref","first-page":"9651","DOI":"10.1523\/JNEUROSCI.0833-09.2009","article-title":"Mesencephalic astrocyte-derived neurotrophic factor is neurorestorative in rat model of Parkinson's disease","volume":"29","author":"Voutilainen","year":"2009","journal-title":"J. Neurosci."},{"issue":"6","key":"10.1016\/j.bbi.2018.01.004_b0425","doi-asserted-by":"crossref","first-page":"3513","DOI":"10.1073\/pnas.051626798","article-title":"Spontaneous corticospinal axonal plasticity and functional recovery after adult central nervous system injury","volume":"98","author":"Weidner","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.bbi.2018.01.004_b0430","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.4049\/jimmunol.154.3.1399","article-title":"Inhibition of lipopolysaccharide-induced IL-1 beta transcription by cyclic adenosine monophosphate in human astrocytic cells","volume":"154","author":"Willis","year":"1995","journal-title":"J. Immunol."},{"key":"10.1016\/j.bbi.2018.01.004_b0435","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1038\/sj.bjp.0702720","article-title":"Comparison of changes in the extracellular concentration of noradrenaline in rat frontal cortex induced by sibutramine or d-amphetamine: modulation by \u03b12-adrenoceptors","volume":"127","author":"Wortley","year":"1999","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bbi.2018.01.004_b0440","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/S0022-3565(24)38271-0","article-title":"\u03b12C adrenoceptors inhibit adenylyl cyclase in mouse striatum: potential activation by dopamine","volume":"289","author":"Zhang","year":"1999","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bbi.2018.01.004_b0445","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.molbrainres.2004.06.029","article-title":"Delayed gene therapy of glial cell line-derived neurotrophic factor is efficacious in a rat model of Parkinson's disease","volume":"134","author":"Zheng","year":"2005","journal-title":"Mol. Brain Res."},{"key":"10.1016\/j.bbi.2018.01.004_b0450","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1358\/dof.2004.029.12.855246","article-title":"Norepinephrine transporter inhibitors and their therapeutic potential","volume":"29","author":"Zhou","year":"2004","journal-title":"Drugs Future"}],"container-title":["Brain, Behavior, and Immunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889159118300059?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889159118300059?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:49:56Z","timestamp":1760168996000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889159118300059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":90,"alternative-id":["S0889159118300059"],"URL":"https:\/\/doi.org\/10.1016\/j.bbi.2018.01.004","relation":{},"ISSN":["0889-1591"],"issn-type":[{"value":"0889-1591","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment with the noradrenaline re-uptake inhibitor atomoxetine alone and in combination with the \u03b12-adrenoceptor antagonist idazoxan attenuates loss of dopamine and associated motor deficits in the LPS inflammatory rat model of Parkinson\u2019s disease","name":"articletitle","label":"Article Title"},{"value":"Brain, Behavior, and Immunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbi.2018.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}